References

A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association.

10.1161/cir.0000000000001186 · 2023 · External reference

Dapagliflozin in patients with chronic kidney disease.

10.1056/nejmoa2024816 · 2020 · External reference

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

10.1056/nejmoa1812389 · 2019 · External reference

Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.

10.1016/j.jchf.2023.05.015 · 2023 · External reference

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

10.1093/eurheartj/ehab777 · 2022 · External reference

Finerenone in heart failure with mildly reduced or preserved ejection fraction.

10.1056/nejmoa2407107 · 2024 · External reference

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomized controlled trials.

10.1016/s2213-8587(24)00271-7 · 2025 · External reference

Temporal trends in prevalence and prognostic implications of comorbidities among patients with acute decompensated heart failure: the ARIC study community surveillance.

10.1161/circulationaha.120.047019 · 2020 · External reference

Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.

10.1002/ejhf.3304 · 2024 · External reference

Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis.

10.1016/j.jacc.2024.05.005 · 2024 · External reference

The American Heart Association Get With The Guidelines program.

10.1016/j.ahj.2004.09.015 · 2004 · External reference

Linking inpatient clinical registry data to Medicare claims data using indirect identifiers.

10.1016/j.ahj.2009.04.002 · 2009 · External reference

Association of dual eligibility for Medicare and Medicaid with heart failure quality and outcomes among Get With The Guidelines–Heart Failure hospitals.

10.1001/jamacardio.2021.0611 · 2021 · External reference

Burden of chronic kidney disease and outcomes following hospitalization for heart failure.

10.1136/heartjnl-2025-327053 · 2026 · External reference

Overcoming the risk-treatment paradox: prescribing GDMT for severe heart failure.

10.1016/j.jchf.2025.01.014 · 2025 · External reference

Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations.

10.1016/j.jacc.2023.04.034 · 2023 · External reference

Sodium-glucose cotransporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.

2024 · External reference

The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment.

10.1016/j.jacc.2025.06.055 · 2025 · External reference

Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design.

10.1016/j.ijcard.2020.04.068 · 2020 · External reference

Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease.

10.1161/circulationaha.123.068524 · 2024 · External reference

Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed.

10.1001/jamacardio.2021.0496 · 2021 · External reference

Simultaneous or rapid initiation of combination therapy for heart failure with preserved ejection fraction.

10.1001/jamacardio.2025.0038 · 2025 · External reference

Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients.

10.1161/circoutcomes.108.822692 · 2009 · External reference